Comparison of the Effects of Dexmedetomidine and Ketamine Infusion on the Inflammatory Response in Liver Resection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-30

Study Completion Date

2023-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Resection is being performed with increasing frequency in the treatment of surgical diseases of the liver. Ischemia-reperfusion injury is a major cause of liver injury occurring during surgical procedures, including hepatic resection and liver transplantation. Dexmedetomidine and ketamine, which are frequently used in anesthesia practice, also have strong anti-inflammatory capacity. The primary aim of this study is to investigate the effect of iv low-dose ketamine and dexmedetomidine infusion on inflammation in liver resection surgery, and the secondary aim is to determine its effect on pain scores.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of the Addition of Dexmedetomidine to Bupivacaine During Supraclavicular Brachial Plexus Blockade

NCT02049970

Sequelae of Fracture of Forearm and Upper Arm

COMPLETED PHASE4

Comparison of the Perioperative Effects of Dexmedetomidine and Ketamine Sedation in Septorhinoplasty Operations

NCT04628559

Anesthesia Intravenous Anesthetic Toxicity

COMPLETED NA

Effect of Deksmedetomidine and Remifentanil in Extubation Agitation

NCT02104297

Agitation

UNKNOWN PHASE4

Effect of Wound Infiltration by Ketamine Versus Dexmedetomidine Added to Bupivacaine on Surgical Stress

NCT02927379

Abdominal Cancer

COMPLETED PHASE3

The Effects of Dexmedetomidine on Peroperative Shivering Incidence Under Spinal Anesthesia

NCT01921361

Perioperative/Postoperative Complications

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

General anesthesia will apply to all patients. Group 1 (Control Group, n=15); After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline.

Group 2 (Ketamine Group, n=15); After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.

Group 3 (Dexmedetomidine Group, n=15); After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.

For biochemical examination, blood will be taken for PEDF (Pigment epithelium-derived factor), Pentraxin 3, Serum amyloid A at the 1st and 12th postoperative hour. AST, ALT, GGT, LDH, bilirubin, CRP and hemogram results, which are routinely checked during these hours, will be recorded.

All the patients were administered 1000 mg iv paracetamol 30 minutes before the surgery ended, and was repeated every 6 hours following the surgery.The postoperative analgesia was evaluated by using VAS(Visual Analogue Scale).The PCA (Patient Controlled Analgesia) device was programmed at 10 μcq concentration with loading dose 50 μcq, 15-minute lock time, 25 μcq bolus without basal infusion, and this was continued for 24 hours in the postoperative recovery room.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammation Analgesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saline

After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline..

Group Type ACTIVE_COMPARATOR

Control Group

Intervention Type PROCEDURE

After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline

Ketamine

After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.

Group Type ACTIVE_COMPARATOR

Ketamine Group

Intervention Type PROCEDURE

After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.

Dexmedetomidine

After intubation, the patient will be infused at a low dose of 1 mg/kg dexmedetomidine for the first 10 minutes, then 0.5 mg/kg/hour

Group Type ACTIVE_COMPARATOR

Dexmedetomidine

Intervention Type PROCEDURE

After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control Group

After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline

Intervention Type PROCEDURE

Ketamine Group

After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.

Intervention Type PROCEDURE

Dexmedetomidine

After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA (American Society of Anaesthesiologists) I-II-III group who will undergo liver resection surgery,
* no known history of heart, kidney, hematological disease, peptic ulcer, gastrointestinal bleeding, allergy, chronic pain
* who agreed to participate in the study

Exclusion Criteria

* Patients with underlying serious cardiovascular disease,
* patients who cannot cooperate, patients who are allergic to one of the drugs to be used
* patients who do not want to participate

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes